The present meta-analysis has demonstrated the benefit of the association of vasopressin and terlipressin in reducing norepinephrine requirements in patients with vasodilatory shock, particularly in patients with septic shock. Our results show that vasopressin treatment is not associated with decreased cardiac output or oxygen delivery and consumption, even in higher doses. However, the pooled analyses showed that higher doses of terlipressin were associated with worsening of these variables. Vasopressin significantly reduces mortality in general patients, and specifically in patients with septic shock…link here